上海家化联合股份有限公司 外汇套期保值业务管理制度 （公司六届十八次董事会通过、八届二十六次董事会修订） 第一章 总则 第一条 为规范上海家化联合股份有限公司（以下简称"公司"）的外汇套 期保值业务，有效防范风险，维护公司及股东利益，根据《中华人民共和国证券 法》、《中华人民共和国公司法》、《上海证券交易所股票上市规则》等法律、 法规以及《公司章程》的有关规定，结合公司的实际情况，特制定本制度。 第二条 本制度所称外汇套期保值业务品种具体包括：远期业务、掉期业务、 互换业务、期权业务及其他外汇衍生产品业务。 第三条 本制度适用于公司及全资或控股子公司，全资或控股子公司进行外 汇套期保值业务视同公司进行外汇套期保值业务。未经公司同意，公司下属全资 及控股子公司不得操作该业务。 第二章 外汇套期保值业务操作规定 第四条 公司进行外汇套期保值业务遵循合法、审慎、安全、有效的原则， 所有外汇套期保值业务均以正常生产经营为基础，以具体经营业务为依托，以规 避和防范汇率或利率风险为目的，不得进行以投机为目的的交易。 第五条 公司进行外汇套期保值交易必须基于公司的外汇收支谨慎预测，外 汇套期保值业务的交割期间需与公司业务的 ...

PERFECT GROUP CORP.,LTD （江苏省扬州市杭集工业园） 倍加洁集团股份有限公司 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证股 东会的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司股东会规则》以及《倍加洁集团股份有限公司章程》等相关规定，倍 加洁集团股份有限公司（以下简称"公司"）特制定本次股东会会议须知，请出 席股东会的全体人员自觉遵守。 请出席会议的股东或股东代理人（以下统称"股东"）及相关人员准时到达会场 签到确认参会资格。股东在参会登记时间内没有通过传真或信函方式登记的，不 在签到表上登记签到的，或会议正式开始后没有统计在会议公布表决权数量之内 的股东，不得参加表决。 倍加洁集团股份有限公司 选择现场投票或网络投票中的一种表决方式，不能重复投票。股东可以在网络投 票时间内通过上海证券交易所的交易系统行使表决权。同一股份通过现场方式和 网络方式重复进行投票的，以第一次投票结果为准。出席本次现场会议的股东， 若已进行会议登记并领取表决票，但未进行投票表决，则视为该股东自动放弃表 决权利，其所持有的表决权在统计表决结果时作弃权处理。 律 ...

Core Viewpoint - The company, Aihua Group, is actively engaging in various sectors including new energy vehicles, photovoltaic, energy storage, wind power, industrial automation, and 5G communications, while also planning to hold its annual shareholder meeting to discuss multiple key proposals [2][3][4]. Group 1: Financial Performance - For the year 2024, the company achieved a revenue of 391,161.84 million yuan, representing a year-on-year growth of 15.76%. However, both operating profit and net profit saw significant declines of 41.11% and 44.68% respectively [3]. - The company plans to distribute a cash dividend of 0.15 yuan per share, totaling 59,816,979 yuan [4]. Group 2: Shareholder Meeting - Aihua Group will hold its annual shareholder meeting on May 22, 2025, to review several proposals including the financial report, profit distribution, and foreign exchange hedging business [3][5]. - The meeting will also address the reappointment of the auditing firm for the fiscal year 2025 [4]. Group 3: Market Activity - On May 13, 2025, Aihua Group's stock closed at 15.45 yuan, with a trading volume of 32,600 shares and a total transaction value of 50.1257 million yuan [1]. - The capital flow on the same day indicated a net inflow of 188.46 million yuan from institutional investors and 270.67 million yuan from speculative funds, while retail investors experienced a net outflow of 459.13 million yuan [2][5].

本周关注点 公司公告汇总 宁波德业科技股份有限公司将于2025年5月21日召开2024年年度股东大会，会议地点为宁波市北仑区甬 江南路26号研发楼7楼。会议将审议多项议案，包括2024年度董事会工作报告、监事会工作报告、独立 董事述职报告、财务决算报告、年度报告及其摘要、利润分配及资本公积金转增股本方案、使用自有资 金进行现金管理、公司及子公司向银行申请综合授信额度及对外担保额度、开展外汇套期保值业务、董 事薪酬方案、监事薪酬方案等。公司及子公司拟使用最高不超过80亿元的自有资金进行现金管理，并向 银行申请不超过200亿人民币的综合授信额度。此外，公司计划开展不超过15亿美元的外汇套期保值业 务。 业绩披露要点 截至2025年5月9日收盘，德业股份（605117）报收于89.5元，较上周的86.2元上涨3.83%。本周，德业 股份5月8日盘中最高价报90.28元。5月6日盘中最低价报86.1元。德业股份当前最新总市值578.14亿元， 在光伏设备板块市值排名4/62，在两市A股市值排名234/5145。 2024年公司实现营业收入112.06亿元，同比增长49.82%，归属于母公司股东的净利润29.60亿元， ...

Core Points - The company is preparing for the 2024 Annual General Meeting (AGM) to discuss various proposals including financial reports, profit distribution, and governance changes [2][3][4] Proposal Summaries - Proposal 1: The company will present the 2024 Board of Directors' Work Report for shareholder approval [3] - Proposal 2: The company will present the 2024 Supervisory Board's Work Report for shareholder approval [3] - Proposal 3: The company will present the 2024 Annual Report and its summary for shareholder approval [3] - Proposal 4: The company will present the 2024 Financial Settlement Report for shareholder approval [3] - Proposal 5: The company proposes a profit distribution plan, distributing cash dividends of RMB 4.50 per 10 shares, totaling RMB 120 million, which is 59.48% of the net profit [3] - Proposal 6: The company will confirm the salaries and allowances for non-independent directors and senior management for 2024, with the chairman receiving RMB 145.41 million [3] - Proposal 7: The company will confirm the salaries and allowances for independent directors for 2024, with the highest being RMB 6.72 million [3] - Proposal 8: The company proposes to reappoint Tianzhi International Accounting Firm for the 2025 financial report and internal control audit, with fees totaling RMB 1 million [4] - Proposal 9: The company plans to use idle funds for cash management to enhance investment returns [4] - Proposal 10: The company will review the execution of daily related transactions for 2024 and the expected amount for 2025 [5] - Proposal 11: The company plans to conduct foreign exchange hedging with a total amount not exceeding RMB 2 billion [6] - Proposal 12: The company plans to provide guarantees for its subsidiary, with amounts not exceeding RMB 2 billion for one subsidiary and RMB 3 billion for another [7] - Proposal 13: The company will sign a financial service agreement with Supply and Marketing Group Financial Co., Ltd. to improve liquidity [8] - Proposal 14: The company plans to change its business scope and amend its articles of association [9] - Proposal 15: The company will revise the rules of procedure for board meetings and shareholder meetings [10] - Proposal 16: The company will revise the independent director working rules and other governance systems [12] - Proposal 17: The company proposes to abolish the supervisory board and its rules [13] Financial Performance - The company reported a revenue of RMB 1,059,581.84 million for the year, an increase of 1.30% compared to the previous year [14] - The raw material prices in the agricultural chemical industry have decreased, with the raw material price index dropping by 9.07% year-on-year [14]

江苏常州 二〇二五年五月二十日 江苏武进不锈股份有限公司（603878） 2024 年年度股东大会会议资料 《关于公司非独立董事（除董事长、副董事长外）薪酬的议案》- 30 - 江苏武进不锈股份有限公司 会议资料 公司登记在册的本公司股东。因故不能亲自出席会议的股东，可以委托授权代理 人参加会议，代理人可以不是本公司股东。 议案八： 江苏武进不锈股份有限公司（603878） 2024 年年度股东大会会议资料 -2- 江苏武进不锈股份有限公司 一、会议时间 ①网络投票系统：上海证券交易所股东大会网络投票系统。 ②网络投票起止时间：自 2025 年 5 月 20 日至 2025 年 5 月 20 日。 ③采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 股东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 二、现场会议地点：江苏省常州市天宁区郑陆镇武澄西路 1 号公司二楼职工 培训室。 三、出席现场会议对象： 四、见证律师：江苏正气浩然律师事务所梁永伟、邹逸韬。 五、现场会议议 ...

Financial Data and Key Metrics Changes - Aflac reported net earnings per diluted share of $0.05, significantly impacted by net investment losses compared to net investment gains in Q1 2024 [5] - Adjusted earnings per diluted share remained unchanged at $1.66 year over year [5][13] - Adjusted return on equity (ROE) was 12.7% excluding foreign currency remeasurement, indicating a solid performance [13] - Adjusted book value per share, excluding foreign currency remeasurement, increased by 2.2% [13] Business Line Data and Key Metrics Changes - Aflac Japan experienced a 12.6% year-over-year sales increase, driven by significant contributions from Sumitas and a 6.3% increase in cancer insurance sales [5][6] - Aflac US saw a 3.5% year-over-year increase in sales, with strong performance in group life, disability, and network dental [8] - Net earned premiums in Aflac Japan declined by 5%, while underlying earned premiums adjusted for deferred profit liability and reinsurance declined by 1.4% [14] - In the US, net earned premiums increased by 1.8%, with persistency rising by 60 basis points year over year to 79.3% [17] Market Data and Key Metrics Changes - Aflac Japan's total benefit ratio was 65.8%, down 120 basis points year over year, while the US total benefit ratio was 47.7%, up 120 basis points year over year [15][18] - Persistency in Japan remained solid at 93.8%, up 40 basis points year over year [16] - The expense ratio in Japan increased to 19.6%, primarily due to higher technology expenses, while the US expense ratio decreased to 37.6% [16][19] Company Strategy and Development Direction - Aflac aims to appeal to younger customers through products like Sumitas, which has been successful in reaching this demographic [6] - The company is focused on maintaining strong premium persistency and driving profitable growth through stronger underwriting discipline [8] - Aflac continues to leverage its strong capital and cash flows while maintaining prudent liquidity and capital management [10] - The company is committed to reinforcing its leading position in the life insurance markets of Japan and the US [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for Aflac's products, emphasizing the importance of being a partner in health for policyholders [9] - The company is optimistic about the growth potential in both Japan and the US, with plans to continue capital deployment and maintain a strong dividend track record [11][12] - Management acknowledged the challenges posed by macroeconomic factors but remains committed to long-term capital management strategies [36] Other Important Information - Aflac repurchased $900 million worth of its own stock and paid $317 million in dividends during Q1 2025 [23] - The company ended the quarter with strong capital ratios, including an estimated regulatory ESR above 250% [24] - Aflac Japan's cancer insurance sales are expected to grow, supported by the launch of a new cancer product in March 2025 [52] Q&A Session Summary Question: Why did the ESR ratio decline in Q1? - Management explained that the decline was due to the strengthening yen, partially offset by higher Japan interest rates and significant dividends flowing from Aflac Japan to Aflac Inc [32] Question: How should capital planning be approached given recent macro changes? - Management stated that capital management is designed with a long-term view, and they do not plan to change their approach significantly despite recent volatility [36] Question: What are the expectations for the new cancer product sales? - Management expressed confidence in the new cancer product's growth, anticipating continued sales increases throughout 2025 [52] Question: How is the competitive landscape for medical insurance in Japan? - Management acknowledged increased competition but emphasized Aflac's pioneering position and unique services that provide a competitive advantage [56] Question: How does the company view the impact of the yen on its operations? - Management noted that while a strengthening yen introduces volatility, it also leads to higher future dividends in dollar terms from Aflac Japan, which offsets some negative impacts [95]

登录新浪财经APP 搜索【信披】查看更多考评等级 本年度公司现金分红总额53,812,057.90元；本年度以现金为对价，采用集中竞价方式已实施的股份回购 金额75,864,030.95元，现金分红和回购金额合计129,676,088.85元，占本年度归属于上市公司股东净利润 的比例136.39%。其中，以现金为对价，采用要约方式、集中竞价方式回购股份并注销的回购（以下简 称回购并注销）金额0元，现金分红和回购并注销金额合计53,812,057.90元，占本年度归属于上市公司 股东净利润的比例56.60%。 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股权激励授予股份回 购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司拟维持每股分配比例不变，相 应调整分配总额。如后续总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交股东大会审议。 （二）是否可能触及其他风险警示情形 公司上市已满三个完整会计年度，本年度净利润为正值且母公司报表年度末未分配利润为正值，公司不 触及其他风险警示情形，具体如下： ■ 二、公司履行的决策程序 （一）董事会会议的召开、审议和 ...

Core Viewpoint - The company has approved a proposal to engage in foreign exchange hedging activities to mitigate risks associated with currency fluctuations as its overseas business grows [1][2]. Group 1: Foreign Exchange Hedging Activities - The company plans to conduct foreign exchange hedging activities, including but not limited to forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, and other foreign exchange derivatives, with a maximum contract amount of up to 10 million USD or equivalent foreign currency [1]. - The authorization for these activities is valid for 12 months from the date of the board's approval, allowing for the funds to be used in a rolling manner within the specified limit [1]. - The board has authorized the general manager to approve daily foreign exchange hedging plans and sign related contracts, with the finance department responsible for the operation and management of these activities [1]. Group 2: Risk Management and Internal Controls - The foreign exchange hedging activities will primarily involve standard forward foreign exchange products and foreign exchange swaps, limited to the main settlement currencies used in the company's operations [2]. - The maximum delivery period for these hedging activities is generally not to exceed 12 months, and the funding for these activities will come from the company's own funds [2]. - The company has implemented strict internal review and risk control measures, including managing accounts receivable actively to prevent delays in delivery for forward foreign exchange contracts [2]. Group 3: Board Approval - The proposal was approved by the company's third board meeting with 7 votes in favor, 0 against, and 0 abstentions, and does not require submission to the shareholders' meeting for further approval [2]. - Relevant documents include the resolution of the third board meeting and the decision from the first special meeting of independent directors in 2025 [2].

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2024, primarily due to falling prices of pesticide products, despite an increase in production and sales volume [18]. Group 1: Company Overview - The company, Haier Pharmaceutical Group Co., Ltd., is engaged in the research, production, and sales of pesticide formulations, intermediates, and raw materials, with a focus on insecticides and fungicides [4][15]. - The pesticide industry is characterized by relatively inelastic demand, playing a crucial role in agricultural production and food security [2][3]. Group 2: Financial Performance - The company achieved operating revenue of CNY 3.91 billion in 2024, a decrease of 11.16% from CNY 4.40 billion in 2023 [18]. - The net profit attributable to shareholders was CNY 181.37 million, down 61.67% from CNY 473.20 million in the previous year [18]. - The net cash flow from operating activities was CNY 285.55 million, a significant decrease of 70.11% compared to CNY 955.35 million in 2023 [18]. Group 3: Market Dynamics - The global demand for pesticides is expected to grow due to increasing food security needs and agricultural efficiency [2]. - China's pesticide production capacity is shifting towards countries like China and India, driven by the expiration of patents and restructuring by multinational agrochemical giants [2][3]. Group 4: Product Development - The company has been diversifying its pesticide offerings, with several new products entering trial production in recent years, including various insecticides and fungicides [4][5]. - The company is focusing on high-efficiency, low-toxicity pesticides to meet the growing market demand [2][4]. Group 5: Industry Trends - The pesticide industry is experiencing a shift towards biopesticides and environmentally friendly products, with increasing market share for biological and chemical pesticides [7]. - The market for generic pesticides is expected to expand as patents expire, providing opportunities for companies with strong R&D capabilities [2][3].